

S2 Table. Treatment of clinical course of hepatocellular carcinoma

	Hypervascular HCC only (Group A)	Hypovascular nodules co-existing with hypervascular HCC (Group B)	<i>P</i>
Total number of treatment, n (%)			
≤ 3	61 (57)	24 (53)	0.722
> 3	46 (43)	21 (47)	
Median (range)	3 (1–9)	3 (1–11)	
Local ablation (excluding initial treatment), n (%)			
Absent	39 (36)	19 (42)	0.584
Present	68 (64)	26 (58)	
TACE, n (%)			
Absent	50 (47)	20 (44)	0.859
Present	57 (53)	25 (56)	
Others, n (%)			
Absent	83 (78)	39 (83)	0.265
Present	24 (22)	6 (17)	
Cause of death, n (%)			
HCC	28 (26)	14 (31)	0.555
Liver dysfunction	13 (12)	10 (22)	0.138
Others	18 (17)	14 (31)	0.080

Abbreviations: HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization